Targeting caspases in cancer therapeutics

Biological Chemistry

Volumn 394, Issue 7, 2013, Pages 831-843

  Hensley, Patrick ^a   Mishra, Murli ^a   Kyprianou, Natasha ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Apoptin; Apoptosis, caspase; Prostate cancer; Quinazolines; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOPTIN; AZACITIDINE; CASPASE; CASPASE 3; CASPASE 8; CHINESE DRUG; DOXORUBICIN; GAMMA INTERFERON; GATAPARSEN; GEMCITABINE; HERBACEOUS AGENT; HISTONE DEACETYLASE INHIBITOR; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; JUSTICIA PROCUMBENS EXTRACT; JUSTICIDIN A; PLANT EXTRACT; PODOPHYLLOTOXIN; RETINOIC ACID; RITUXIMAB; SEPANTRONIUM BROMIDE; SPC 3042; SURVIVIN; TERAMEPROCOL; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; CANCER ADJUVANT THERAPY; CANCER GENE THERAPY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG TARGETING; ENZYME STRUCTURE; EPIGENETICS; FEVER; GENE EXPRESSION REGULATION; HUMAN; JUSTICIA (PLANT); JUSTICIA PROCUMBENS; LUNG NON SMALL CELL CANCER; MEDICINAL PLANT; MOLECULARLY TARGETED THERAPY; NEOPLASM; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

APOPTOSIS; CASPASE INHIBITORS; CASPASES; CELL PROLIFERATION; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84881177777     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2013-0128     Document Type: Review

References (144)

1. Adida, C., Crotty, P.L., McGrath, J., Berrebi, D., Diebold, J., and Altieri, D.C. (1998). Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Pathol. 152, 43-49.
2. Aggarwal, S., Kim, S.W., Cheon, K., Tabassam, F.H., Yoon, J.H., and Koo, J.S. (2006). Nonclassical action of retinoic acid on the activation of the cAMP response element-binding protein in normal human bronchial epithelial cells. Mol. Biol. Cell. 17, 566-575.
3. Alnemri, E., Livingston, D., Nicholson, D., Salvesen, G., Thornberry, N., Wong, W., and Yuan, J. (1996). Human ICE/CED-3 Protease Nomenclature. Cell 87, 171.
4. Altieri, D.C. (2008). Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 8, 61-70.
5. Altieri, D.C. (2006). The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr. Opin. Cell. Biol. 18, 609-615.
6. Andersen, M.H., Soerensen, R.B., Becker, J.C., and Thor Straten, P. (2006). HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer. J. Transl. Med. 4, 38.
7. Aoki, Y., Feldman, G.M., and Tosato, G. (2003). Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101, 1535-1542.
8. Backendorf, C., Visser, A.E., de Boer, A.G., Zimmerman, R., Visser, M., Voskamp, P., Zhang, Y.H., and Noteborn, M. (2008). Apoptin: therapeutic potential of an early sensor of carcinogenic transformation. Annu. Rev. Pharmacol. Toxicol. 48, 143-169.
9. Banelli, B., Casciano, I., Croce, M., Di Vinci, A., Gelvi, I., Pagnan, G., Brignole, C., Allemanni, G., Ferrini, S., Ponzoni, M., and Romani, M. (2002). Expression and methylation of CASP8 in neuroblastoma: identification of a promoter region. Nat. Med. 8, 1333-1335.
10. Banks, D.P., Plescia, J., Altieri, D.C., Chen, J., Rosenberg, S.H., Zhang, H., and Ng, S.C. (2000). Survivin does not inhibit caspase-3 activity. Blood 96, 4002-4003.
11. Beltinger, C., Fulda, S., Kammertoens, T., Meyer, E., Uckert, W., and Debatin, K.M. (1999). Herpes simplex virus thymidine kinase/ ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc. Natl. Acad. Sci. USA 96, 8699-8704.
12. Benning, C.M. and Kyprianou, N. (2002). Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Cancer Res. 62, 597-602.
13. Burek, M., Maddika, S., Burek, C.J., Daniel, P.T., Schulze-Osthoff, K., and Los, M. (2006). Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent. Oncogene. 25, 2213-2222.
14. Carrasco, R.A., Stamm, N.B., Marcusson, E., Sandusky, G., Iversen, P., and Patel, B.K. (2011). Antisense inhibition of survivin expression as a cancer therapeutic. Mol. Cancer Ther. 10, 221-232.
15. Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70.
16. Casciano, I., De Ambrosis, A., Croce, M., Pagnan, G., Di Vinci, A., Allemanni, G., Banelli, B., Ponzoni, M., Romani, M., and Ferrini, S. (2004). Expression of the caspase-8 gene in neuroblastoma cells is regulated through an essential interferon-sensitive response element (ISRE). Cell Death Differ. 11, 131-134.
17. Chang, C.C., Heller, J.D., Kuo, J., and Huang, R.C. (2004). Tetra-Omethyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc. Natl. Acad. Sci. USA 101, 13239-13244.
18. Church, D.N. and Talbot, D.C. (2012). Survivin in solid tumors: rationale for development of inhibitors. Curr. Oncol. Rep. 14, 120-128.
19. Clackson, T., Yang, W., Rozamus, L.W., Hatada, M., Amara, J.F., Rollins, C.T., Stevenson, L.F., Magari, S.R., Wood, S.A., Courage, N.L., et al. (1998). Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc. Natl. Acad. Sci. USA 95, 10437-10442.
20. Danen-Van Oorschot, A.A., Fischer, D.F., Grimbergen, J.M., Klein, B., Zhuang, S., Falkenburg, J.H., Backendorf, C., Quax, P.H., Van der, E.b A.J., and Noteborn, M.H. (1997). Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc. Natl. Acad. Sci. USA 94, 5843-5847.
21. Danen-Van Oorschot, A.A., Zhang, Y.H., Leliveld, S.R., Rohn, J.L., Seelen, M.C., Bolk, M.W., Van Zon, A., Erkeland, S.J., Abrahams, J.P., Mumberg, D., et al. (2003). Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. J. Biol. Chem. 278, 27729-27736.
22. Darnell, J.E. Jr., Kerr, I.M., and Stark, G.R. (1994). Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421.
23. Eggert, A., Grotzer, M.A., Zuzak, T.J., Wiewrodt, B.R., Ho, R., Ikegaki, N., and Brodeur, G.M. (2001). Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)- induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res. 61, 1314-1319.
24. Ehrlich, M. (2009). DNA hypomethylation in cancer cells. Epigenomics 1, 239-259.
25. Favaloro, B., Allocati, N., Graziano, V., Di Ilio, C., and De Laurenzi, V. (2012). Role of apoptosis in disease. Aging (Albany NY) 4, 330-349.
26. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. International Vidaza High-Risk MDS Survival Study Group. (2009). Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 10, 223-232.
27. Fiandalo, M.V. and Kyprianou, N. (2012). Caspase control: protagonists of cancer cell apoptosis. Exp. Oncol. 34, 165-175.
28. Fuchs, Y. and Steller, H. (2011). Programmed cell death in animal development and disease. Cell 147, 742-758.
29. Fuentes-Prior, P. and Salvesen, G.S. (2004). The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J. 384, 201-232.
30. Fukamiya, N. and Lee, K.H. (1986). Antitumor agents, 81. Justicidin-A and diphyllin, two cytotoxic principles from Justicia procumbens. J. Nat. Prod. 49, 348-350.
31. Fulciniti, M., Amin, S., Nanjappa, P., Rodig, S., Prabhala, R., Li, C., Minvielle, S., Tai, Y.T., Tassone, P., Avet-Loiseau, H., Hideshima, T., et al. (2011). Significant biological role of sp1 transactivation in multiple myeloma. Clin. Cancer Res. 17, 6500-6509.
32. Fulda, S. and Debatin, K.M. (2006). 5-Aza-2'-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene. 25, 5125-5133.
33. Fulda, S. and Debatin, K.M. (2002). IFN γ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21, 2295-2308.
34. Fulda, S., Küfer, M.U., Meyer, E., van Valen, F., Dockhorn- Dworniczak, B., and Debatin, K.M. (2001). Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20, 5865-5877.
35. Garrison, J.B., Shaw, Y.J., Chen, C.S., and Kyprianou, N. (2007). Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Res. 67, 11344-11352.
36. Geiger, K., Hagenbuchner, J., Rupp, M., Fiegl, H., Sergi, C., Meister, B., Kiechl-Kohlendorfer, U., Müller, T., Ausserlechner, M.J., and Obexer, P. (2012). FOXO3/FKHRL1 is activated by 5-aza-2-deoxycytidine and induces silenced caspase-8 in neuroblastoma. Mol. Biol. Cell 23, 2226-2234.
37. Ghobrial, I.M., Witzig, T.E., and Adjei, A.A. (2005). Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55, 178-194.
38. Giaccone, G., Zatloukal, P., Roubec, J., Floor, K., Musil, J., Kuta, M., van Klaveren, R.J., Chaudhary, S., Gunther, A., and Shamsili, S. (2009). Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J. Clin. Oncol. 27, 4481-4486.
39. Gillies, R.J., Verduzco, D., and Gatenby, R.A. (2012). Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat. Rev. Cancer 12, 487-493.
40. Grotzer, M.A., Eggert, A., Zuzak, T.J., Janss, A.J., Marwaha, S., Wiewrodt, B.R., Ikegaki, N., Brodeur, G.M., and Phillips, P.C. (2000). Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 19, 4604-4610.
41. Grossman, S.A., Ye, X., Peereboom, D., Rosenfeld, M.R., Mikkelsen, T., Supko, J.G., and Desideri, S.; Adult Brain Tumor Consortium. (2012). Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro. Oncol. 14, 511-517.
42. Guelen, L., Paterson, H., Gäken, J., Meyers, M., Farzaneh, F., and Tavassoli, M. (2004). TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene 23, 1153-1165.
43. Guha, M., Plescia, J., Leav, I., Li, J., Languino, L.R., and Altieri, D.C. (2009). Endogenous tumor suppression mediated by PTEN involves survivin gene silencing. Cancer Res. 69, 4954-4958.
44. Gyurkocza, B., Plescia, J., Raskett, C.M., Garlick, D.S., Lowry, P.A., Carter, B.Z., Andreeff, M., Meli, M., Colombo, G., and Altieri, D.C. (2006). Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J. Natl. Cancer Inst. 98, 1068-1077.
45. Hansen, J.B., Fisker, N., Westergaard, M., Kjaerulff, L.S., Hansen, H.F., Thrue, C.A., Rosenbohm, C., Wissenbach, M., Orum, H., and Koch, T. (2008). SPC3042: a proapoptotic survivin inhibitor. Mol. Cancer Ther. 7, 2736-2745.
46. Hanahan, D. and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
47. He, X.L., Zhang, P., Dong, X.Z., Yang, M.H., Chen, S.L., and Bi, M.G. (2012). JR6, a new compound isolated from Justicia procumbens, induces apoptosis in human bladder cancer EJ cells through caspase-dependent pathway. J. Ethnopharmacol. 144, 284-292.
48. Hensley, P.J. and Kyprianou, N. (2012). Modeling prostate cancer in mice: limitations and opportunities. J. Androl. 33, 133-144.
49. Hopkins-Donaldson, S., Bodmer, J.L., Bourloud, K.B., Brognara, C.B., Tschopp, J., and Gross, N. (2000). Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 60, 4315-4319.
50. Herman, J.G. and Baylin, S.B. (2003). Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042-2054.
51. Hirohashi, Y., Torigoe, T., Maeda, A., Nabeta, Y., Kamiguchi, K., Sato, T., Yoda, J., Ikeda, H., Hirata, K., Yamanaka, N., et al. (2002). An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumorassociated protein, survivin. Clin. Cancer Res. 8, 1731-1739.
52. Iwasa, T., Okamoto, I., Suzuki, M., Nakahara, T., Yamanaka, K., Hatashita, E., Yamada, Y., Fukuoka, M., Ono, K., and Nakagawa, K. (2008). Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin. Cancer Res. 14, 6496-6504.
53. Iwasa, T., Okamoto, I., Takezawa, K., Yamanaka, K., Nakahara, T., Kita, A., Koutoku, H., Sasamata, M., Hatashita, E., Yamada, Y., et al. (2010). Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br. J. Cancer 103, 36-42.
54. Jacob, N.K., Cooley, J.V., Shirai, K., and Chakravarti, A. (2012). Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation. Onco. Targets Ther. 5, 7-20.
55. Jänicke, R.U. (2009). MCF-7 breast carcinoma cells do not express caspase-3. Breast Cancer Res. Treat. 117, 219-221.
56. Jänicke, R.U., Sprengart, M.L., Wati, M.R., and Porter, A.G. (1998). Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 273, 9357-9360.
57. Jiang, S.Y., Wu, M.S., Chen, L.M., Hung, M.W., Lin, H.E., Chang, G.G., and Chang, T.C. (2005). Identification and characterization of the retinoic acid response elements in the human RIG1 gene promoter. Biochem. Biophys. Res. Commun. 331, 630-639.
58. Jiang, M., Zhu, K., Grenet, J., and Lahti, J.M. (2008). Retinoic acid induces caspase-8 transcription via phospho-CREB and increases apoptotic responses to death stimuli in neuroblastoma cells. Biochim. Biophys. Acta 1783, 1055-1067.
59. Jiang, Y., Saavedra, H.I., Holloway, M.P., Leone, G., and Altura, R.A. (2004). Aberrant regulation of survivin by the RB/E2F family of proteins. J. Biol. Chem. 279, 40511-40520.
60. Kawasaki, H., Altieri, D.C., Lu, C.D., Toyoda, M., Tenjo, T., and Tanigawa, N. (1998). Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58, 5071-5074.
61. Khanna, N., Dalby, R., Tan, M., Arnold, S., Stern, J., and Frazer, N. (2007). Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol. Oncol. 107, 554-562.
62. Kaminskas, E., Farrell, A.T., Wang, Y.C., Sridhara, R., and Pazdur, R. (2005). FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10, 176-182.
63. Kaplan, D.H., Shankaran, V., Dighe, A.S., Stockert, E., Aguet, M., Old, L.J., and Schreiber, R.D. (1998). Demonstration of an interferon γ -dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95, 7556-7561.
64. Keledjian, K. and Kyprianou, N. (2003). Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. J. Urol. 169, 1150-1156.
65. Kim, S.W., Hong, J.S., Ryu, S.H., Chung, W.C., Yoon, J.H., and Koo, J.S. (2007). Regulation of mucin gene expression by CREB via a nonclassical retinoic acid signaling pathway. Mol. Cell. Biol. 27, 6933-6947.
66. Kita, A., Mitsuoka, K., Kaneko, N., Nakata, M., Yamanaka, K., Jitsuoka, M., Miyoshi, S., Noda, A., Mori, M., Nakahara, T., et al. (2012). Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab. J. Pharmacol. Exp. Ther. 343, 178-183.
67. Kohno, T., Morishita, K., Takano, H., Shapiro, D.N., and Yokota, J. (1994). Homozygous deletion at chromosome 2q33 in human small-cell lung carcinoma identified by arbitrarily primed PCR genomic fingerprinting. Oncogene 9, 103-108.
68. Kumar, B., Yadav, A., Lang, J.C., Cipolla, M.J., Schmitt, A.C., Arradaza, N., Teknos, T.N., and Kumar, P. (2012). YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels. Mol. Cancer. Ther. 11, 1988-1998.
69. Kyprianou, N. and Benning, C.M. (2000). Suppression of human prostate cancer cell growth by1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res. 60, 4550-4555.
70. Kyprianou, N., Litvak, J.P., Borkowski, A., Alexander, R., and Jacobs, S.C. (1998). Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J. Urol. 159, 1810-1815.
71. Lepor, H. (2007). Alpha blockers for the treatment of benign prostatic hyperplasia. Rev. Urol. 9, 181-190.
72. Lladser, A., Sanhueza, C., Kiessling, R., and Quest, A.F. (2011). Is survivin the potential Achilles'heel of cancer? Adv. Cancer. Res. 111, 1-37.
73. Li, C., Wu, Z., Liu, M., Pazgier, M., and Lu, W. (2008). Chemically synthesized human survivin does not inhibit caspase-3. Protein Sci. 17, 1624-1629.
74. Liedtke, C., Gröger, N., Manns, M.P., and Trautwein, C. (2006). Interferon-enhances TRAIL-mediated apoptosis by up-regulating caspase-8 transcription in human hepatoma cells. J. Hepatol. 44, 342-249.
75. Liedtke, C., Zschemisch, N.H., Cohrs, A., Roskams, T., Borlak, J., Manns, M.P., and Trautwein, C. (2005). Silencing of caspase-8 in murine hepatocellular carcinomas is mediated via methylation of an essential promoter element. Gastroenterology 129, 1602-1615.
76. Liu, Y., Wei, D., Zhao, Y., Cheng, W., Lu, Y., Ma, Y., Li, X., Han, C., Wei, Y., Cao, H., et al. (2012). Synthesis and biological evaluation of a series of podophyllotoxins derivatives as a class of potent antitubulin agents. Bioorg. Med. Chem. 20, 6285-6295.
77. Los, M., Panigrahi, S., Rashedi, I., Mandal, S., Stetefeld, J., Essmann, F., and Schulze-Osthoff, K. (2009). Apoptin, a tumor-selective killer. Biochim. Biophys. Acta 1793, 1335-1342.
78. Lyons, R.M. (2012). Myelodysplastic syndromes: therapy and outlook. Am. J. Med. 125, S18 - S23.
79. Maddika, S., Mendoza, F.J., Hauff, K., Zamzow, C.R., Paranjothy, T., and Los, M. (2006). Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol. Ther. 5, 10-19.
80. Martin, S.J., Henry, C.M., and Cullen, S.P. (2012). A perspective on mammalian caspases as positive and negative regulators of inflammation. Mol. Cell 46, 387-397.
81. Masetti, R., Biagi, C., Zama, D., Vendemini, F., Martoni, A., Morello, W., Gasperini, P., and Pession, A. (2012). Retinoids in pediatric onco-hematology: the model of acute promyelocytic leukemia and neuroblastoma. Adv. Ther. 29, 747-762.
82. Matsuo, T. and Thiele, C.J. (1998). p27Kip1: a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line. Oncogene 16, 3337-3343.
83. McKenzie, S. and Kyprianou, N. (2006). Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J. Cell. Biochem. 97, 18-32.
84. Mitsiades, N., Poulaki, V., Mitsiades, C., and Tsokos, M. (2001). Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res. 61, 2704-2712.
85. Murakami, Y., Matsuya, T., Kita, A., Yamanaka, K., Noda, A., Mitsuoka, K., Nakahara, T., Miyoshi, S., and Nishimura, S. (2013). Radiosynthesis, biodistribution and imaging of [(11) C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model. Nucl. Med. Biol. 40, 221-226.
86. Mu ñ oz-Pinedo, C. (2012). Signaling pathways that regulate life and cell death: evolution of apoptosis in the context of self-defense. Adv. Exp. Med. Biol. 738, 124-143.
87. Nakahara, T., Kita, A., Yamanaka, K., Mori, M., Amino, N., Takeuchi, M., Tominaga, F., Hatakeyama, S., Kinoyama, I., Matsuhisa, A., et al. (2007). YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 67, 8014-8021.
88. Nakahara, T., Yamanaka, K., Hatakeyama, S., Kita, A., Takeuchi, M., Kinoyama, I., Matsuhisa, A., Nakano, K., Shishido, T., Koutoku, H., et al. (2011). YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs 22, 454-462.
89. Natesan, S., Kataria, J.M., Dhama, K., Bhardwaj, N., and Sylvester, A. (2006). Anti-neoplastic effect of chicken anemia virus VP3 protein (apoptin) in Rous sarcoma virus-induced tumours in chicken. J. Gen. Virol. 87, 2933-2940.
90. Negrini, S., Gorgoulis, V.G., and Halazonetis, T.D. (2012). Genomic instability - an evolving hallmark of cancer. Nat. Rev. Mol. Cell. Biol. 11, 220-228.
91. Ocker, M. and Höpfner, M. (2012). Apoptosis-modulating drugs for improved cancer therapy. Eur. Surg. Res. 48, 111-120.
92. Ogasawara, J., Suda, T., and Nagata, S. (1995). Selective apoptosis of CD4 + CD8 + thymocytes by the anti-Fas antibody. J. Exp. Med. 181, 485-491.
93. Olijslagers, S.J., Zhang, Y.H., Backendorf, C., and Noteborn, M.H. (2007). Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells. Basic Clin. Pharmacol. Toxicol. 100, 127-131.
94. Partin, J.V., Anglin, I.E., and Kyprianou, N. (2003). Quinazolinebased alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-signalling and I Binduction. Br. J. Cancer 88, 1615-1621.
95. Pietersen, A.M., van der, Eb M.M., Rademaker, H.J., van den Wollenberg, D.J., Rabelink, M.J., Kuppen, P.J., van Dierendonck, J.H., van Ormondt, H., Masman, D., van de Velde, C.J., et al. (1999). Specific tumor-cell killing with adenovirus vectors containing the apoptin gene. Gene Ther. 6, 882-892.
96. Poon, I.K., Oro, C., Dias, M.M., Zhang, J.P., and Jans, D.A. (2005). A tumor cell-specific nuclear targeting signal within chicken anemia virus VP3/apoptin. J. Virol. 79, 1339-1341.
97. Redfern, C.P., Lovat, P.E., Malcolm, A.J., and Pearson, A.D. (1995). Gene expression and neuroblastoma cell differentiation in response to retinoic acid: differential effects of 9- cis and all- trans retinoic acid. Eur. J. Cancer 31A, 486-494.
98. Rennebeck, G., Martelli, M., and Kyprianou, N. (2005). Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? Cancer Res. 65, 11230-11235.
99. Rohn, J.L., Zhang, Y.H., Aalbers, R.I., Otto, N., Den Hertog, J., Henriquez, N.V., Van De Velde, C.J., Kuppen, P.J., Mumberg, D., Donner, P., et al. (2002). A tumor-specific kinase activity regulates the viral death protein Apoptin. J. Biol. Chem. 277, 50820-50827.
100. Ruiz-Ruiz, C., Mu ñoz-Pinedo, C., and López-Rivas, A. (2000). Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptorinduced mitochondria-operated apoptotic program. Cancer Res. 60, 5673-5680.
101. Ruiz-Ruiz, C., Ruiz de Almodóvar, C., Rodríguez, A., Ortiz-Ferrón, G., Redondo, J.M., López-and Rivas A. (2004). The up-regulation of human caspase-8 by interferon- γ in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1. J. Biol. Chem. 279, 19712-19720.
102. Sakamoto, S. and Kyprianou, N. (2010). Targeting anoikis resistance in prostate cancer metastasis. Mol. Aspects. Med. 31, 205-214.
103. Sakamoto, S., Schwarze, S., and Kyprianou, N. (2011). Anoikis disruption of focal adhesion-Akt signaling impairs renal cell carcinoma. Eur. Urol. 59, 734-744.
104. Salvesen, G.S. and Duckett, C.S. (2002). IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell. Biol. 3, 401-410.
105. Salvesen, G.S. and Riedl, S.J. (2008). Caspase mechanisms. Adv. Exp. Med. Biol. 615, 13-23.
106. Sartor, A.O. and Fitzpatrick, J.M. (2012). Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC). BJU Int. 110, 328-335.
107. Satoh, T., Okamoto, I., Miyazaki, M., Morinaga, R., Tsuya, A., Hasegawa, Y., Terashima, M., Ueda, S., Fukuoka, M., Ariyoshi, Y., et al. (2009). Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin. Cancer Res. 15, 3872-3 880.
108. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K.J., Debatin, K.M., Krammer, P.H., and Peter, M.E. (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17, 1675-1687.
109. Schroder, K. and Tschopp, J. (2012). The inflammasomes. Cell 140, 821-832.
110. Shariat, S.F., Desai, S., Song, W., Khan, T., Zhao, J., Nguyen, C., Foster, B.A., Greenberg, N., Spencer, D.M., and Slawin, K.M. (2001). Adenovirus-mediated transfer of inducible caspases: a novel " death switch " gene therapeutic approach to prostate cancer. Cancer Res. 61, 2562-2571.
111. Shivapurkar, N., Toyooka, S., Eby, M.T., Huang, C.X., Sathyanarayana, U.G., Cunningham, H.T., Reddy, J.L., Brambilla, E., Takahashi, T., Minna, J.D., et al. (2002). Differential inactivation of caspase-8 in lung cancers. Cancer Biol. Ther. 1, 65-69.
112. Shore, N., Mason, M., and de Reijke, T.M. (2012). New developments in castrate-resistant prostate cancer. BJU Int. 109, 22-32.
113. Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62, 220-241.
114. Siegelin, M.D., Plescia, J., Raskett, C.M., Gilbert, C.A., Ross, A.H., and Altieri, D.C. (2010). Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma. Mol. Cancer Ther. 9, 1638-1646.
115. Sonnemann, J., Hartwig, M., Plath, A., Saravana Kumar, K., Müller, C., and Beck, J.F. (2006a). Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells. Cancer Lett. 232, 148-160.
116. Sonnemann, J., Kumar, K.S., Heesch, S., Müller, C., Hartwig, C., Maass, M., Bader, P., and Beck, J.F. (2006b). Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int. J. Oncol. 28, 755-766.
117. Sonnemann, J., Dreyer, L., Hartwig, M., Palani, C.D., Hong le, T.T., Klier, U., Bröker, B., Völker, U., and Beck, J.F. (2007). Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. J. Cancer Res. Clin. Oncol. 133, 847-858.
118. Storm van's Gravesande, K., Layne, M.D., Ye, Q., Le, L., Baron, R.M., Perrella, M.A., Santambrogio, L., Silverman, E.S., and Riese, R.J. (2002). IFN regulatory factor-1 regulates IFN- γ -dependent cathepsin S expression. J. Immunol. 168, 4488-4494.
119. Su, C.L., Huang, L.L., Huang, L.M., Lee, J.C., Lin, C.N., and Won, S.J. (2006). Caspase-8 acts as a key upstream executor of mitochondria during justicidin A-induced apoptosis in human hepatoma cells. FEBS Lett. 580, 3185-3191.
120. Tamm, I., Wang, Y., Sausville, E., Scudiero, D.A., Vigna, N., Oltersdorf, T., and Reed, J.C. (1998). IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58, 5315-5320.
121. Tanioka, M., Nokihara, H., Yamamoto, N., Yamada, Y., Yamada, K., Goto, Y., Fujimoto, T., Sekiguchi, R., Uenaka, K., Callies, S., et al. (2011). Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 68, 505-511.
122. Tavassoli, M., Guelen, L., Luxon, B.A, and Gäken, J. (2005). Apoptin: specific killer of tumor cells? Apoptosis 10, 717-724.
123. Taylor, S.M. and Jones, P.A. (1982). Changes in phenotypic expression in embryonic and adult cells treated with 5-azacytidine. J. Cell Physiol. 111, 187-194.
124. Teitz, T., Wei, T., Valentine, M.B., Vanin, E.F., Grenet, J., Valentine, V.A., Behm, F.G., Look, A.T., Lahti, J.M., et al. (2000). Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 6, 529-535.
125. Tekautz, T.M., Zhu, K., Grenet, J., Kaushal, D., Kidd, V.J., and Lahti, J.M. (2006). Evaluation of IFN-gamma effects on apoptosis and gene expression in neuroblastoma - preclinical studies. Biochim. Biophys. Acta 1763, 1000-1010.
126. Thiele, C.J., Reynolds, C.P., and Israel, M.A. (1985). Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313, 404-406.
127. Teodoro, J.G., Heilman, D.W., Parker, A.E., and Green, M.R. (2004). The viral protein Apoptin associates with the anaphasepromoting complex to induce G2/M arrest and apoptosis in the absence of p53. Genes Dev. 18, 1952-1957.
128. Tolcher, A.W., Mita, A., Lewis, L.D., Garrett, C.R., Till, E., Daud, A.I., Patnaik, A., Papadopoulos, K., Takimoto, C., Bartels, P., et al. (2008). Phase I and pharmacokinetic study of YM155, a smallmolecule inhibitor of survivin. J. Clin. Oncol. 26, 5198-5203.
129. Tsuruma, T., Hata, F., Torigoe, T., Furuhata, T., Idenoue, S., Kurotaki, T., Yamamoto, M., Yagihashi, A., Ohmura, T., Yamaguchi, K., et al. (2004). Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J. Transl. Med. 2, 19.
130. Velculescu, V.E., Madden, S.L., Zhang, L., Lash, A.E., Yu, J., Rago, C., Lal, A., Wang, C.J., Beaudry, G.A., Ciriello, K.M., et al. (1999). Analysis of human transcriptomes. Nat. Genet. 23, 387-388.
131. Wang, R.H., Zheng, Y., Kim, H.S., Xu, X., Cao, L., Luhasen, T., Lee, M.H., Xiao, C., Vassilopoulos, A., Chen, W., et al. (2008). Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol. Cell 32, 11-20.
132. Wang, L., Chen, S., Xue, M., Zhong, J., Wang, X., Gan, L., Lam, E.K., Liu, X., Zhang, J., Zhou, T., et al. (2012). Homeobox D10 gene, a candidate tumor suppressor, is downregulated through promoter hypermethylation and associated with gastric carcinogenesis. Mol. Med. 18, 389-400.
133. Wiley, S.R., Schooley, K., Smolak, P.J., Din, W.S., Huang, C.P., Nicholl, J.K., Sutherland, G.R., Smith, T.D., Rauch, C., and Smith, C.A. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682.
134. Wu, Y., Alvarez, M., Slamon, D.J., Koeffler, P., and Vadgama, J.V. (2010). Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer. 10, 32.
135. Xiaojiang, T., Jinsong, Z., Jiansheng, W., Chengen, P., Guangxiao, Y., and Quanying, W. (2010). Adeno-associated virus harboring fusion gene NT4-ant-shepherdin induce cell death in human lung cancer cells. Cancer Invest. 28, 465-471.
136. Xie, X., Zhao, X., Liu, Y., Zhang, J., Matusik, R.J., Slawin, K.M., and Spencer, D.M. (2001). Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res. 61, 6795-6804.
137. Yamanaka, K., Nakahara, T., Yamauchi, T., Kita, A., Takeuchi, M., Kiyonaga, F., Kaneko, N., and Sasamata, M. (2011). Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin. Cancer Res. 17, 5423-5431.
138. Yang, X., Merchant, M.S., Romero, M.E., Tsokos, M., Wexler, L.H., Kontny, U., Mackall, C.L., and Thiele, C.J. (2003). Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosisinducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res. 63, 1122-1129.
139. Ye, J., Ortaldo, J.R., Conlon, K., Winkler-Pickett, R., and Young, H.A. (1995). Cellular and molecular mechanisms of IFN- γ production induced by IL-2 and IL-12 in a human NK cell line. J. Leukoc Biol. 58, 225-233.
140. Yoon, D.H., Shin, J.S., Jin, D.H., Hong, S.W., Jung, K.A., Kim, S.M., Hong, Y.S., Kim, K.P., Lee, J.L., Suh, C., et al. (2012). The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2. Anticancer Res. 32, 1681-1688.
141. Zaidi, M.R. and Merlino, G. (2011). The two faces of interferon- γ in cancer. Clin. Cancer Res. 17, 6118-6124.
142. Zhang, X.D., Franco, A., Myers, K., Gray, C., Nguyen, T., and Hersey, P. (1999a). Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAILinduced apoptosis of melanoma. Cancer Res. 59, 2747-2753.
143. Zhang, Y.H., Abrahams, P.J., van der, Eb A.J., and Noteborn, M.H. (1999b). The viral protein Apoptin induces apoptosis in UV-C-irradiated cells from individuals with various hereditary cancer-prone syndromes. Cancer Res. 59, 3010-3015.
144. Zhang, Y.H., Leliveld, S.R., Kooistra, K., Molenaar, C., Rohn, J.L., Tanke, H.J., Abrahams, J.P., and Noteborn, M.H. (2003). Recombinant Apoptin multimers kill tumor cells but are nontoxic and epitope-shielded in a normal-cell-specific fashion. Exp. Cell Res. 289, 36-46.